Online Inquiry
FANCG (-/-) Cell Line
SPL-01352
| Size | Price |
| 1 Unit | Online Inquiry |
| Description |
|---|
| FANCG (-/-) |
| Target Information | |
|---|---|
| Target Name | FANCG |
| Gene Abbr. | FANCG |
| Gene ID | 2189 |
| Full Name | FA complementation group G |
| Alias | FAG, XRCC9 |
| Species | Human |
| Genomic Locus | 9p13 |
| Introduction | The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group G. [provided by RefSeq, Jul 2008]. |
| Product Details | |
|---|---|
| Cell Line Model | RKO |
| Genotype | FANCG (-/-) |
| Description | FANCG (-/-) |
| Parental ATCC ID | CRL-2577 |
| STR Profile | Amelogenin: X; CSF1PO: 8, 10; D13S317: 8, 11; D16S539: 12, 13; D5S818: 11, 13; D7S820: 8, 10; THO1: 6, 10; TPOX:11; vWA: 15, 16, 17; ATCC |
| Disease | Carcinoma |
| Tissue | Colon |
| Gender | Female |
| Key Endogenous Mutations | BRAF, NF1, PIK3CA |
| CVT Selection Condition | No antibiotic resistance |
| Cell Number | 1x10^6 |
| Handling Specifications | |
|---|---|
| Revival | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 70-80% confluency, approximately 1:6-1:15. |
| Culture Medium | RPMI 1640 including 2 mM L-glutamine and 25 mM sodium bicarbonate, supplemented with 10% FBS. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 70-80% confluency, approximately 1:6-1:15. |
| Freeze Medium | Complete growth media 45% + USDA approved FBS 50% + DMSO 5% |
| Biosafety Level | BSL-1 |
| Disclaimer | This product is classified under IATA regulations as a GMMO (genetically modified micro-organism) and will ship as UN3245. If applicable, ensure facility meets all requirements per local and country regulations. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.